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unleashing the CD8 T cell mediated anti-tumor
activity results in significant, unprecedented
clinical efficacy in various solid tumors
Emanuela Romano1,2,3 and Pedro Romero3*Abstract
The role of immune checkpoints in modulating the magnitude as well as the functional profile of T cell responses
is increasingly understood in molecular detail. Antibody-mediated blockade of co-inhibitory receptors has been
shown to restore T cell function in both chronic viral infections and cancer. The latter has been successfully translated
to new therapeutic options in the treatment of cancer. Indeed, monoclonal antibodies blocking either CTLA-4 or PD-1
have recently been approved for the treatment of metastatic melanoma in the United States, Europe and Japan. In
this commentary, we summarize and put into perspective five letters recently published back to back in the
November 27 (2014) issue of Nature reporting on different immunological and clinical aspects of blockade of
the PD-1/PD-L1 pathway in tumor bearing hosts. Notably, treatment with anti-PD-L1 blocking antibody was
shown result in profound clinical responses in patients with several solid tumor including bladder, lung and head and
neck carcinomas among others. These five simultaneous publications highlight the tremendous therapeutic potential
of targeting the PD-1/PD-L1 immune checkpoint and emphasize the need to identify appropriate biomarkers to guide
their optimal clinical application.
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Among the many strategies that cancer cells deploy to
hijack the host immune defenses, blocking of the so-called
immune checkpoints represents one that is showing
promise to trigger a successful counter attack. Several
complex safeguards are intrinsically involved in keeping
the immune system from overreacting to a stimulus or
mistaking a component of “self” for a dangerous invader.
The programmed death 1 (PD-1) pathway is one such
checkpoint regulating inflammatory responses in tissues.
One or both of the PD-1 ligands, PD-L1 and PD-L2,
expressed on cells in the tissues, can bind to PD-1 recep-
tors on T cells and inhibit their function. Blocking the* Correspondence: pedro.romero@unil.ch
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article, unless otherwise stated.interaction between PD-1 and its ligands can result in en-
hancement of T cell activation and effector functions
resulting in a swift tissue inflammatory response [1].
Main text
Five letters recently published back to back in the same
issue of Nature (November 27th 2014) provide key ex-
perimental evidence on the emerging and critical role of
immune therapy and more specifically, the role of im-
munotherapeutic antibodies that can block PD-1/PD-L1
interactions, in the treatment of cancer. In addition, they
illustrate how technical progress increases the pace of
identifying novel immunogenic somatic mutations as
targets for the treatment of metastatic cancer [2-6]. The
study by Herbst et al. was designed to evaluate the
single-agent safety, activity and associated biomarkers of
PD-L1 inhibition using the MPDL3280A, a humanizedCentral. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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ous infusion every 3 weeks (q3w) to patients with locally
advanced or metastatic solid tumors or haematological
malignancies [2]. Across multiple cancer types, responses
as per RECIST v1.1 (Response Evaluation Criteria in Solid
Tumors, version 1.1) were observed in patients with tu-
mors expressing relatively high levels of PD-L1, particu-
larly when PD-L1 was expressed by tumor-infiltrating
immune cells. Specimens were scored as IHC 0, 1, 2, or 3
if <1%, ≥1% but <5%, ≥5% but <10%, or ≥ 10% of cells per
area were PD-L1 positive, respectively. In the 175 efficacy-
evaluable patients, confirmed objective responses were ob-
served in 32 of 175 (18%), 11 of 53 (21%), 11 of 43 (26%),
7 of 56 (13%) and 3 of 23 (13%) of patients with all tumor
types, non-small cell lung cancer (NSCLC), melanoma,
renal cell carcinoma and other tumors (including colorec-
tal cancer, gastric cancer, and head and neck squamous
cell carcinoma). Interestingly, a striking correlation of re-
sponse to MPDL3280A treatment and tumor-infiltrating
immune cell PD-L1 expression was observed. In sum-
mary, 83% of NSCLC patients with a tumor-infiltrating
immune cell IHC score of 3 responded to treatment,
whereas 43% of those with IHC 2 only achieved disease
stabilization. In contrast, most progressing patients
showed a lack of PD-L1 upregulation by either tumor
cells or tumor-infiltrating immune cells. We would then
speculate that immune therapies targeting the PD-L1/
PD-1 pathway might be especially effective in tumors
where this immune suppressive axis is operational, and
that reversing the balance towards an immune protect-
ive environment would rekindle and strengthen a pre-
existing anti-tumor immune response. Conversely, the
observation of unhindered progression in those pa-
tients, whose tumors lacked PD-L1 expression in the in-
filtrating immune cells suggests that PD-L1 blockade
either fails to promote the induction of de novo anti-
tumor CD8 T cell immunity or the induced anti-tumor
T cells are prevented from efficiently infiltrating the tu-
mors. Other scenarios are of course possible. For in-
stance, the dominance of strongly suppressive factors in
the tumor milieu that potently inhibits local release of
IFN-g thus failing to induce PD-L1 expression in the
tumor milieu. Several candidates include TGF-b, IDO,
iNOS the latter leading to the generation metabolic me-
diators of T cell dysfunction.
A companion study of MPDL3280A validates and ex-
tends upon those findings highlighting the relevance of
the PD-1–PD-L1 pathway for the treatment of meta-
static urothelial bladder cancer (UBC), a disease with
unsatisfactory treatment options and dismal prognosis
[3]. MPDL3280A had noteworthy activity in metastatic
UBC, with responses often rapid and many occurring at
the time of the first response assessment (6 weeks). This
study also confirmed that tumors expressing PD-L1-positive tumor-infiltrating immune cells had particularly
high response rates. A response rate of 43% (95% CI:
26–63%) achieved in advanced UBC patients with PD-
L1 IHC 2/3 tumors provides evidence of noteworthy
clinical activity of MPDL3280A in this setting and com-
pares favorably with that previously seen with single-
agent salvage regimens [7-10]. In addition, patients with
PD-L1 IHC 0/1 tumors had a response rate of only 11%
(95% CI: 4–26%). Of note, responses reported in both
studies were also rapid and occurred even in patients
with poor prognostic features. The safety results with
MPDL3280A are encouraging as most patients did not
require additional intervention– especially in patients
with UBC, who are often older and have a higher inci-
dence of renal impairment suggesting MPDL3280A
may be a better option compared to chemotherapy in
this patient population. Clearly, these data show that
MPDL3280A is most effective in patients in whom the
PD-L1/PD-1 pathway is operational to dampen pre-
existing immunity. The rather unusual rapid clinical
response suggests the reactivation of tumor reactive ef-
fector T cells upon antibody treatment. If so, this sug-
gests the interesting possibility that tumor infiltrating
T cells are inhibited but retain enough functional po-
tential to eliminate efficiently tumors upon release
from PD-1 mediated inhibition. Both phase I studies
followed an adaptive design to allow for tumor-specific
and biomarker (PD-L1 positive) enriched cohorts. An
immediate benefit of this proof-of-concept trial design
is that precious information can be collected more effi-
ciently on the drug, its dosage, and on potential bio-
markers of response. From an ethical perspective, this
innovative design will spare more patients from receiv-
ing doses that are predictably ineffective or in irrele-
vant settings, and thereby ultimately allow for a more
rapid assignment of alternative and potentially life-
saving medicines.
Therapies that target PD-1 receptor have also shown
unprecedented rates of durable clinical responses across
several advanced solid cancers [11-13]. Using quantita-
tive imaging technologies and next-generation sequen-
cing for T cell receptors (TCRs), Tumeh and colleagues,
analysed samples from 46 patients with metastatic mel-
anoma obtained before and during anti-PD-1 therapy
(pembrolizumab) and showed that responding patients
had increased numbers of proliferating CD8 T cells [4].
Strikingly, they observed that pre-treatment samples
from responding patients showed higher numbers of
CD8 T cells with a clonal TCR repertoire in close prox-
imity with PD-1- and PD-L1-expressing cells at the inva-
sive tumor margin and within the tumor itself. With the
aim to define reliable biomarkers of response to PD-1
blockade, the authors, using multivariate analysis, built a
model based on CD8 T cell density at the invasive margin
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This further established the relevance of a pre-existing
density of CD8+ T cells located at the invasive tumor
margins as a biomarker of response in this patient cohort.
Given the profound clinical implications of such observa-
tions, their prospective validation in a randomized, con-
trolled clinical trial is warranted. In this regard, help is
underway from other quarters. Indeed, in an effort to pro-
mote the immune classification of cancer as part of the
routine diagnostic and prognostic assessment of tumors, a
worldwide task force was initiated and the Immunoscore
Project was launched in 2012 (http://www.sitcancer.org/
about-sitc/initiatives/immunoscore). Altogether these data ex-
tend upon similar findings in the response to PD-L1 im-
munomodulatory antibodies and highlight that successful
outcome relies upon a common mechanistic activity,
whereby adaptive PD-1/PD-L1 upregulation thwarts a
pre-existing CD8-mediated immune response that can be
successfully rescued by blocking this immune inhibitory
axis. It is however intriguing that the ensuing reactivated
CD8 T cell responses be long lived. From an immuno-
logical stand point it is tempting to speculate that part of
the reactivated CD8 T cells are of the memory lineage ra-
ther than purely effector T cells, as it has recently been
suggested for a novel understanding of CD8 T cell exhaus-
tion in chronic viral infection and tumors [14].
In addition to classic tumor-associated tumor antigens,
numerous malignant tumors bear the potential of in-
creased immunogenicity because of their high number
of somatic mutations, depicting a mutational landscape
extremely variable at the inter- and intra-patient level
[15-17]. Most tumor mutations are point mutations in
genes encoding intracellular proteins. Short peptide frag-
ments derived from these neo-proteins, via intracellular
processing and presentation at the cell surface as major
histocompatibility complex class I molecules (MHCI) li-
gands, can elicit adaptive T cell responses. It is reason-
able to expect that mutated antigen-specific T cells bear
high affinity antigen receptors since they would not have
been subjected to central tolerance. Until recently, there
were no practical approaches to exploit the mutanome
from tumors. The use of molecular cloning or biochem-
ical approaches provided a trickle of immunogenic mu-
tations. However, the development of several algorithms
that can predict which peptides will bind to given MHC
molecules are now powerful enough to establish mutant
antigen discovery pipelines [18-22]. Yadav and colleagues
sought to simplify the discovery of such immunogenic
mutant peptides by characterizing their properties [5].
Adopting two mouse models (MC-38 and TRAMP-C1),
they combined whole-exome and transcriptome sequen-
cing analyses with mass spectrometry to identify neo-
epitopes. Of the more than 1,300 amino acid changes
identified, about 13% were predicted to bind MHC Class1, a small fraction of which was validated by mass spec-
trometry. Using dedicated algorithms, the peptides were
structurally modelled bound to MHCI. Vaccination of
mice confirmed each predicted immunogenic peptide
in vivo yielding therapeutically active T-cell responses.
These compelling findings highlight that tumor muta-
tions are useful reservoirs of exploitable neo-antigens.
Using a similar approach, Castle et al. analyzed the
mutanome of the widely used B16 melanoma cell line
and tested 50 MHC-binding m-peptides, 16 of which
were immunogenic and 11 of which preferentially rec-
ognized the mutant peptide over the wild-type coun-
terpart. Importantly, they showed that vaccination with
2 of those suppressed the growth of established B16
melanomas [23].
In a time of intense quest for personalized modalities
for cancer therapy, immune interventions that aim at
priming or boosting anti-tumor immune responses tai-
lored to mutational heterogeneity holds much promise.
Consistent with this concept, Gubin et al. employed
genomics and bioinformatics approaches to identify
tumor-specific mutant proteins as a class of T-cell rejec-
tion antigens following anti-PD-1 and/or anti-CTLA-4
therapy. They demonstrate that in mice bearing aggressive
sarcomas therapeutic synthetic long-peptide vaccines in-
corporating these mutant epitopes induced tumor rejec-
tion comparably to checkpoint blockade immunotherapy
[6]. One potential caveat of this study, as is true in similar
tumor models, is to what extent chemically-induced,
highly immunogenic murine tumors reproduce the biol-
ogy of human cancers. We speculate that the TCR reper-
toire in responding patients should be largely overlapping
and show oligoclonal expansion, and that mutational load
should correspond to signs of CD8 T cell proliferation and
activation. This has been elegantly shown in a patient with
advanced melanoma responding to ipilimumab ther-
apy, where cancer exome-guided analysis of T-cell reactiv-
ity revealed a specific response against two neoantigens,
whose magnitude increased significantly upon therapy
[18]. This has also been observed in a series of melanoma
patients, where somatic neoepitopes that elicited an anti-
tumor response were augmented by and associated to
clinical response to CTLA-4 blockade [24].
Conclusions
Blockade of the immune-inhibitory PD-L1–PD-1 path-
way has shown remarkable efficacy in patients with ad-
vanced NSCLC, melanoma, renal-cell cancer, and
Hodgkin’s lymphoma including upon failure to several
lines of therapy [13,25-27]. According to the recent litera-
ture, blockade seemed particularly effective in subjects
with pre-existing cellular immune response [7-10]. Upreg-
ulation of the PD-1–PD-L1 signaling axis in tumor tissue,
as a consequence of type I IFN activation and invasion by
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blockade alone. PD-L1 expression – particularly, by the
tumor-infiltrating immune cells warrants prospective val-
idation as a potential biomarker in clinical trials investigat-
ing PD-1–PD-L1 antibody-containing regimens. However,
the need of a CLIA-based standardized assay for PD-L1
expression and the substantial complexity of the tumor–
host cross-talk should be taken into account as they might
influence outcome with respect to any single or combined
intervention.
The recent results have clear and immediate clinical
effects: anti–PD-1–PD-L1 therapy will become the foun-
dation of the oncology panoply, possibly sparing patients
toxic effects of chemotherapy, where deep investigation
into tumor mutational load and immune interventions
could usher a new wave of promising therapies. We pre-
dict that the list of cancers sensitive to such therapeutic
intervention will also extend to other cancers, including
colorectal adenocarcinoma (especially that harbouring
microsatellite instability) and other gastrointestinal can-
cers, and mesothelioma. As demonstrated in the setting
of Hodgkin’s lymphoma, the mechanism(s) of response
to anti–PD-1 therapy need(s) further study. Although
Hodgkin’s lymphoma is characterized by genetically
driven PD-L1 and PD-L2 overexpression and an inflam-
matory response, evidence for a tumor antigen-specific
response has not yet been described.
With recent data showing impressive clinical activity
of PD-1 or PD-L1 antagonists in subgroups of patients
with a variety of different cancers, the critical and foun-
dational role of immune interventions in cancer treat-
ment is becoming a reality and treatment indications are
becoming more clearly defined. However, a subset of
cancers are poorly infiltrated with immune cells (i.e. at
least one third of all metastatic melanomas) [28] and,
consistent with recently published work patients bearing
tumors, in which type I IFN–regulated genes, T cell–re-
lated genes, and PD-L1 are expressed at low levels, have
comparatively poor prognosis [29,30]. Thus, understand-
ing the profile of this patient subgroup will most likely
pay off, possibly revealing the diversity of mechanisms
controlling antitumor immunity and suggesting new strat-
egies to promote cancer immunity and clinical benefit.
Immune therapies promoting CD8 T cell infiltration of tu-
mors should help in patients not responding or relapsing
on these treatments. Our expectation is that, in this cater-
gory of patients amongst the modalities to augment tumor
immunogenicity, the optimization of vaccines and oncoly-
tic viruses in synergistic combination with checkpoint
blockers or costimulatory receptor agonists are promising.
Chemotherapeutic and targeted agents, as well as radi-
ation therapy are also being exploited in this context, as
data have shown that each of those approaches can induce
immunogenic cell death, intra-tumoral infiltration ofimmune cells, and increase in antigen presentation, re-
spectively. Moreover, the combination of checkpoint in-
hibitors or costimulatory receptor agonists with cytokines
such as IL-2, IL-15 or type I interferons could be tested in
patients not responding or relapsing on these treatments.
Finally, as the tumor hijacks vascularization during its nat-
ural history, one potential synergism to augment clinical
benefit could be the combination of immunotherapy with
biologic agents to normalize tumor vasculature allowing
better immune cell influx to the tumor. These recent
years of immunotherapy success presage the substantial
additional gains that could be achieved from continued
research endeavours in this field and substantiate the
dedication of the so many investigators in the game.
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